Friday, July 29, 2022 Daily Archives

Core Biogenesis bags $10.5m funding to drive plant-based bioproduction

by

Core Biogenesis has completed a $10.5 million Series A funding round, which will be used to build a plant-based bioproduction facility. The site will be located in Strasbourg, France and the firm said it will be dedicated to manufacturing growth factors and cytokines for the cell therapy space and cellular agricultural industry and will launch early next year. The firm claims it has developed a technology platform that can express recombinant proteins from the seeds of a Camelina sativa oilseed…

July 29, 2022

Legend Bio looks to raise $250m in public offering

by

CAR-T firm Legend Biotech has announced plans to raise $250 million by selling American Depositary Shares (ADSs) in an underwritten public offering. In February, New Jersey-Nanjing cell therapy company Legend was approved to launch its BCMA CAR-T therapy, Carvykti, for multiple myeloma in the US, and EU approval followed in May. The company partners the drug with Johnson & Johnson’s Janssen subsidiary. At the recent ASCO convention, Legend revealed the CAR-T had not reached a median progression of disease or…

July 29, 2022

Cytiva opens Vancouver robotic aseptic filling site

by

The site located in the greater Vancouver area will expand manufacturing capacity of aseptic filling machines by over 200%, says Cytiva. The 126,200 square-foot site is situated next to Fraser River in Burnaby, which is less than twenty minutes from Vancouver International Airport, and one hour away from the US border. Work is still ongoing at the existing production site, which the firm acquired from Vanrx Pharmasystems in February 2021, but the firm said a larger space was needed due…

July 29, 2022